Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection

Mohssen Toosi; Mohammad Hassanabadi

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue All Issues In Press Articles Accepted Manuscripts Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Contact Us Support

APC

Authors Guide Submit Manuscript

Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection

Author(s):

Mohssen Nassiri Toosi^1,*,

Mohammad Sadeghi Hassanabadi²

1Department of Internal Medicine & Imam Khomeini Hospital, Tehran University of Medical Sciences, mohssen_nasiri@yahoo.com, Tehran, IR.Iran

2Department of Otolyrngology Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR.Iran

Hepatitis Monthly:Vol. 4, issue 7; 79-82

Article type:Case Report

How to Cite:Mohssen Nassiri ToosiMohammad Sadeghi HassanabadiHearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection.Hepat Mon.4(7):79-82.

Abstract

Hearing loss has been reported on interferons therapy. Combination therapy of pegylated (PEG)-IFN alfa2a plus ribavirin is the current optimal therapy for hepatitis C infection. PEG-INF side effect profile is reported similar in different studies, but with the increasing long-term use of PEG-INF several new adverse effects have been recognized. However, hearing loss has only been recorded once. We report a case of sensorineural hearing loss occurring in a patient with chronic hepatitis C treated with PEG-IFN plus ribavirin and recovered partially one month after the discontinuation of PEG-INF. The ototoxicity would be more serious with the use of PEG-INF. Patients on therapy with this drug should be monitored for auditory disability. The ototoxicity is reversible with discontinuation of drug if the diagnosis is made early in the course.

Keywords

Article

Full Text

Full text is available in PDF

comments